Drug Profile
AR 2201
Alternative Names: AR2201Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute
- Developer AR Pharma
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA (Parenteral)
- 29 Mar 2018 Preclinical trials in Chronic lymphocytic leukaemia in USA (Parenteral) before March 2018 (AR Pharma pipeline, March 2018)